In the mRNA-CRID-001 trial, researchers are evaluating the safety, effectiveness, and immune response of investigational mRNA vaccines and how they work in the body. Research dedicated to understanding immune system responses can provide valuable insights during the development of new medicines and treatments, including mRNA vaccines.
The purpose of this clinical trial is to analyze the human body’s response to several mRNA vaccines and an approved flu vaccine. Each participant will receive between 1 and 3 doses of a single vaccine in the clinical trial. Of the 4 different mRNA vaccines tested in this trial, 3 are investigational (still being researched), and 1 has been approved for the prevention of COVID-19. Since people may respond differently to medical treatments and vaccines, it is important to identify similarities, differences, and patterns between how mRNA vaccines work in the body to protect against viruses.
Participation in this trial will last up to 19 months.
Participants will need to go to one of the clinical trial sites taking part in this trial.
Sites are located in the cities/states identified with the red pin:
Participation in this clinical trial lasts up to 19 months and includes up to 20 in-person trial site visits and 5 phone calls.
The vaccines being evaluated in this clinical trial include:
Participants will be randomly selected to receive 1 of the following:
Participants’ onsite visits may include medical examinations like a physical exam, nasal swab, or blood draw.
Participants will have occasional phone calls with the clinical trial staff. During these phone calls, the clinical trial doctor and medical staff will check how the participant is feeling and ask for updates on their health.
Participants will be asked to use an eDiary app on their smartphone or trial-provided device to complete entries about any symptoms for the duration of the clinical trial.
Insurance is not needed to join this clinical trial, and compensation for your time and travel may be provided.